Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patients with Atr
January 22, 2025 17:00 ET | Source: Anthos Therapeutics Secondary endpoints also…
European Commission approves RYBREVANT (amivantamab) in combination with LAZCLUZE (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
This multitargeted, chemotherapy-free combination demonstrated superiority over osimertinib monotherapy for the first-line…
Paris 2024 Report Confirms over 50% Carbon Emissions Reduction
20 December 2024 - The Olympic and Paralympic Games Paris 2024 achieved an unprecedented 54.6%…
Mangosteen Marvel MangoSoothe Outperforms Leading Joint Health Supplements
Naiad's MangoSoothe changed joint health with its single-ingredient mangosteen formula, showing results…
RadNet Secures Commitments to Amend its Credit Facility, Resulting in 0.25% Reduction in Interest Rates
November 22, 2024 11:00 ET | Source: RadNet, Inc. LOS ANGELES, Nov.…
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban
November 16, 2024 16:38 ET | Source: Anthos Therapeutics Data presented at…